
Donor Blood Cell-based Platform
Unlike the commonly used αβ T cells that are restricted to autologous application only, γδ T cells may provide a potent “off-the-shelf” cytotoxic cell source to treat cancers in different recipients without causing graft-versus-host disease.
CytoMed’s donor blood cell-based CAR-γδ T cell technology

Industry-friendly features of our CAR-γδ T cell technology
OTHERS
CYTOMED
CAR-αβ T cell technology
CAR-γδ T cell technology
Patient’s blood cells, potential issues include Limited cell number due to leukopenia or young age Poor cell quality due patient’s conditions or previous treatments Contamination of leukaemia cells or circulating tumour cells
Healthy donor’s blood cells, advantages include Guaranteed cell number Reasonable cell quality No contamination of cancer cells
Invasive leukapheresis to collect immune cells
Simple blood draw to collect blood sample
Complicated manufacturing process include Washing leukocytes out of apheresis products using a cell washer Enriching lymphocytes via counterflow centrifugal elutriation expanding and transducing T cells using beads and lentiviral vectors
Simpler manufacturing process include mononuclear cell isolation γδ T cell expansion mRNA electroporation
Lentivirus, potential issues include The risk of secondary cancers due to insertional mutagenesis in CAR-αβ T cells or contamination of cancer cells The risk of long-term adverse effects due to persistence of CAR-αβ T cells
mRNA electroporation, advantages include No risk of secondary cancers No risk of long-term adverse effects
CAR-grafted αβ T cells
CAR-grafted γδ T cells
Autologous use, applicable to a single patient only
Allogeneic use, applicable to many patients
Highly personalized “made-to-order” product, very expensive
“Off-the-shelf” product, less expensive